Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th
BETHESDA, Md. -- May 13, 2013
Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP), a global
pharmaceutical company, today announced that it will host a meeting to discuss
the recent opioid-induced constipation (OIC) indication approval for its
flagship product, AMITIZA, on May 20, 2013, from 9:00 to 10:30AM ET in
Orlando, FL. Members of Sucampo’s management team and two key outside experts
will provide a market update, overview of the scientific data, and clinical
perspectives relevant to OIC.
If you would like to attend the event in Orlando, please RSVP to
email@example.com as space is limited.
Those interested in accessing the live audio webcast of the teleconference may
do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar
and should log on 10 to 15 minutes before the meeting begins in order to
download any software required. Presentation slides will be available via the
webcast links. A replay of the webcast will also be available on the Company’s
website for several days after the live event. Alternatively, participants may
dial 866-515-2907 (domestic) or 617-399-5121 (international) and use passcode
24996242. A replay of the teleconference will be available by dialing
888-286-8010 (domestic) or 617-801-6888, passcode 41707791, approximately two
hours after the teleconference concludes. The archive of the teleconference
will remain available for 30 days.
About Opioid Induced Constipation (OIC)
OIC is a common adverse effect of chronic opioid use. Binding of opioids to
peripheral opioid receptors in the gastrointestinal tract results in
absorption of electrolytes, such as chloride, and subsequent reduction in
small intestinal fluid. In addition, activation of enteric opioid receptors
results in abnormal GI motility. Together, these processes result in OIC,
which is characterized by infrequent and incomplete evacuation of stool, hard
stool consistency, and straining associated with bowel movements.
About lubiprostone (AMITIZA^®)
AMITIZA (lubiprostone) is a prostone, a locally acting chloride channel
activator, indicated for the treatment of chronic idiopathic constipation
(CIC) in adults and OIC in adults with chronic, non-cancer pain (24 mcg twice
daily) and for irritable bowel syndrome with constipation (8 mcg twice daily)
in women 18 years of age and older in the United States. In Japan,
lubiprostone (24 mcg twice daily) is indicated for the treatment of chronic
constipation (excluding constipation caused by organic diseases). In
Switzerland, lubiprostone (24 mcg twice daily) is indicated for the treatment
of CIC. In the U.K., lubiprostone (24 mcg twice daily) is indicated for the
treatment of CIC and associated symptoms in adults.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please
AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the
tagline, The Science of Innovation, are registered trademarks of Sucampo AG.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo's
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo
incorporates by reference.
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
Press spacebar to pause and continue. Press esc to stop.